| Unknown | Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Breast Cancer, Renal Cell Carcinoma | Phase 2 | 2019-12-17 |
| Completed | Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Uroth Bladder Cancer, Urothelial Carcinoma, Solid Tumor | Phase 2 | 2019-09-25 |
| Unknown | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-54 Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E) | Phase 1 | 2015-12-01 |
| Completed | IPI-926 Extension Protocol for Continuation of Treatment With IPI-926 Basal Cell Carcinoma, Chondrosarcoma | N/A | 2012-03-01 |
| Completed | A Phase 2 Study With IPI-926 in Patients With Myelofibrosis Primary Myelofibrosis, Fibrosis, Bone Marrow | Phase 2 | 2011-10-01 |
| Completed | Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lu Non-small Cell Lung Cancer | Phase 1 / Phase 2 | 2011-07-01 |
| Completed | A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer Non Small Cell Lung Cancer | Phase 2 | 2011-05-01 |
| Completed | A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma Conventional Chondrosarcoma | Phase 2 | 2011-02-01 |
| Terminated | Dose Escalation of IPI-493 in Hematologic Malignancies Hematologic Malignancies | Phase 1 | 2010-06-01 |
| Completed | A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | 2010-04-01 |
| Withdrawn | Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma Dedifferentiated Liposarcoma | Phase 2 | 2010-01-01 |
| Terminated | Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breas Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer | Phase 2 | 2009-03-01 |
| Completed | A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies Neoplasms | Phase 1 | 2008-09-01 |
| Terminated | Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Gastrointestinal Stromal Tumors | Phase 3 | 2008-08-01 |
| Terminated | A Phase 1 Dose Escalation Study of IPI-493 Advanced Malignancies | Phase 1 | 2008-07-01 |
| Terminated | A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma Metastatic Melanoma | Phase 2 | 2008-02-01 |
| Completed | Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors Solid Tumors | Phase 1 | 2007-12-01 |
| Completed | A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Ca Prostate Cancer, Prostatic Neoplasms, Cancer of the Prostate | Phase 2 | 2007-11-01 |
| Completed | Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer ( Lung Cancer | Phase 1 / Phase 2 | 2007-01-01 |
| Completed | Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS) Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas | Phase 1 | 2005-12-01 |
| Completed | Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma Multiple Myeloma | Phase 1 | 2005-06-01 |